Evidence map›Paper›PMID 38245714›Full record

ReviewCancer cell international2024

B cells in head and neck squamous cell carcinoma: current opinion and novel therapy.

Xinyue Guo, Licheng Xu, Luan Nie, Chenyu Zhang, Yaohui Liu, Rui Zhao, Jing Cao, Linli Tian, Ming Liu

Abstract readReview
In one paragraph

Review in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xinyue GuoDepartment of Otorhinolaryngology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Licheng XuDepartment of Otorhinolaryngology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Luan NieDepartment of Otorhinolaryngology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Chenyu ZhangDepartment of Otorhinolaryngology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Yaohui LiuDepartment of Otorhinolaryngology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Rui ZhaoDepartment of Otorhinolaryngology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. cczzww110@163.com.
Jing CaoDepartment of Otorhinolaryngology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Linli TianDepartment of Otorhinolaryngology, The First Affiliated Hospital of Harbin Medical University, Harbin, China. tianlinli78@163.com.
Ming LiuDepartment of Otorhinolaryngology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. liumingent@163.com.ORCID http://orcid.org/0000-0002-5957-0142

Funding

National Natural Science Foundation of China 82072987National Natural Science Foundation of China 82173209
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumour. Despite advancements in surgery, radiotherapy and chemotherapy, which have improved the prognosis of most patients, a subset of patients with poor prognoses still exist due to loss of surgical opportunities, postoperative recurrence, and metastasis, among other reasons. The tumour microenvironment (TME) is a complex organization composed of tumour, stromal, and endothelial cells. Communication and interaction between tumours and immune cells within the TME are increasingly being recognized as pivotal in inhibiting or promoting tumour development. Previous studies on T cells in the TME of HNSCC have yielded novel therapeutic possibilities. However, the function of B cells, another adaptive immune cell type, in the TME of HNSCC patients has yet to be determined. Recent studies have revealed various distinct subtypes of B cells and tertiary lymphoid structures (TLSs) in the TME of HNSCC patients, which are believed to impact the efficacy of immune checkpoint inhibitors (ICIs). Therefore, this paper focuses on B cells in the TME to explore potential directions for future immunotherapy for HNSCC.

Indexed as

B cellHNSCCPrognosisTherapyTME

Identifiers

PMID38245714
PMCPMC10799521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.